Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences.

Shiraki, Kimiyasu; Sato, Noriaki; Sakai, Kaoru; Matsumoto, Shirou; Kaszynski, Richard H; Takemoto, Masaya

Shiraki, Kimiyasu; Sato, Noriaki; Sakai, Kaoru; Matsumoto, Shirou; Kaszynski, Richard H; Takemoto, Masaya.

Afiliación

Shiraki K; Senri Kinran University, Suita, Osaka, Japan. Electronic address: k-shiraki@cs.kinran.ac.jp.
Sato N; Department of Biomedical Data Intelligence, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Sakai K; Department of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Matsumoto S; Department of Pediatrics, Graduate School of Medical Sciences, Kumamoto University, Japan.
Kaszynski RH; Stanford Solutions, Stanford University School of Medicine, Stanford, CA 94305, USA.
Takemoto M; Department of Microbiology, Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, Japan.

Pharmacol Ther ; 235: 108121, 2022 07.

Article en En | MEDLINE | ID: mdl-35121001

Asunto(s)

Tratamiento Farmacológico de COVID-19; Infecciones por Citomegalovirus; Gripe Humana; Amidas/uso terapéutico; Antivirales/farmacología; Antivirales/uso terapéutico; Prueba de COVID-19; Infecciones por Citomegalovirus/tratamiento farmacológico; Humanos; Gripe Humana/tratamiento farmacológico; Pirazinas; SARS-CoV-2

Palabras clave

Antiviral therapy; COVID-19; Favipiravir; Innate and adaptive immunity; RNA dependent RNA polymerase; SARS-CoV-2

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones por Citomegalovirus / Gripe Humana / Tratamiento Farmacológico de COVID-19 Límite: Humans Idioma: En Revista: Pharmacol Ther Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google